Our development is supported by an international network of academic, clinical and industrial collaborators
Establishing a network of agreements and collaborations with academic laboratories, clinical centres and industrial leaders is at the heart of Innate Pharma’s strategy. We are constantly looking for opportunities for collaboration in the field of antibodies in immuno-oncology and chronic inflammatory diseases.
Innate Pharma has had a partnership for 10 years with Novo Nordisk A/S, resulting in three first-in-class monoclonal antibodies currently in clinical trials. The most advanced programmes in our portfolio, lirilumab and monalizumab, are respectively developed by our partners Bristol-Myers Squibb (license agreement) and AstraZeneca (co-development and commercialization agreement). Innate Pharma is also collaborating with Sanofi (research collaboration and licensing agreement) for the development of innovative bispecific antibody formats.
The Company is also collaborating with a large number of world leading cancer centres and clinical networks such as, in France, the cooperative groups ALFA et GOELAMS, the Institut Gustave Roussy and the Hôpital Saint Louis in Paris, the Institut Paoli-Calmettes in Marseille; and in the United States, the Ohio State’s James Cancer Hospital, the Dana-Farber Cancer Institute, the Memorial Sloan-Kettering Cancer Center, and the National Cancer Institutes (NCI).
Since inception, Innate Pharma has collaborated with leading academic teams in the field of the biology of the immune system and innate immunity, notably the INSERM ( French National Institute of Health and Medical Research) and CNRS ( French National Centre for Scientific Research) teams; the Centre d’Immunologie Marseille-Luminy (CIML), in France; the Universities of Genoa and Perugia in Italy, the Institut Paul Scherrer in Switzerland or the Ohio State University, Berkeley and Stanford universities in the United States. The Company has demonstrated its commitment to collaborative projects, as is shown today by its product pipeline, resulting to a large degree from fruitful academic collaborations.
Innate Pharma's teams are able to generate antibodies to validate a target, including selection and development of a candidate for clinical trials. We are sponsor of exploratory clinical trials from the beginning of the process to the achievement of clinical proof of concept.
If you are interested in collaborating with Innate Pharma
Marseille Immunopole, a world-class cluster in immunology
Innate Pharma is in the heart of Marseille scientific ecosystem, focused on research in immunology for more than 30 years. The company is drawn from local academic research and particularly of the CIML (Center of Immunology Marseille-Luminy) one of the largest European centers for immunology and a major contributors to the area of science upon which the Company was developed.
In Marseille, Innate Pharma also has the advantage of being close to a life sciences training and education hub and a cancer centre (Paoli-Calmettes Institute) that contribute to the development of outstanding translational research. This expertise is now concentrated within the Marseille Immunopôle cluster, supported by Eurobiomed, a non-for-profit organisation which has been accredited by the French government as a "competitive cluster".
Innate Pharma is a component part of Marseille Immunopole which brings together key players in the immunology area to form one of the largest immunology and development centers in Europe.
One of the first structuring projects of Marseille Immunopôle is the centre of ImmunTechnology of Marseille (MI-mAbs) a 19 million euros investment funded by the French government program (PIA).
Supported by the University of Aix Marseille (AMU), the project was launched in 2012.